Triple‐negative breast cancer: Present challenges and new perspectives

Wiley - Tập 4 Số 3 - Trang 209-229 - 2010
Franca Franca, Lutgarde M.C. Lutgarde M.C., Hadassa Hadassa, Riet Riet, Edda Edda, Ingrid S. Ingrid S., Sabine Sabine, Hanneke Hanneke, Jan Jan, Daniel Daniel, Geert J. Geert J., Nicole Nicole, Filippo Filippo, Hans Hans, Hege G. Hege G., Therese Therese, Elda Elda, Anne-Lise Anne-Lise

Tóm tắt

Triple‐negative breast cancers (TNBC), characterized by absence of estrogen receptor (ER), progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), are typically associated with poor prognosis, due to aggressive tumor phenotype(s), only partial response to chemotherapy and present lack of clinically established targeted therapies. Advances in the design of individualized strategies for treatment of TNBC patients require further elucidation, by combined ‘omics’ approaches, of the molecular mechanisms underlying TNBC phenotypic heterogeneity, and the still poorly understood association of TNBC with BRCA1 mutations. An overview is here presented on TNBC profiling in terms of expression signatures, within the functional genomic breast tumor classification, and ongoing efforts toward identification of new therapy targets and bioimaging markers. Due to the complexity of aberrant molecular patterns involved in expression, pathological progression and biological/clinical heterogeneity, the search for novel TNBC biomarkers and therapy targets requires collection of multi‐dimensional data sets, use of robust multivariate data analysis techniques and development of innovative systems biology approaches.

Tài liệu tham khảo

10.1001/jama.299.13.1574 10.1016/j.molonc.2008.11.003 10.1677/erc.1.01059 10.1186/1471-2105-10-S12-S16 10.1136/jcp.2005.029264 10.1038/modpathol.3800483 10.1016/S1359-6349(09)72031-2 10.1200/JCO.2007.14.2646 10.1002/cncr.23226 10.1007/s10549-006-9400-z 10.1002/cncr.22618 Belkic K., 2004, Current dilemmas and future perspectives for breast cancer screening with a focus on optimization of magnetic resonance spectroscopic imaging by advances in signal processing, Isr. Med. Assoc. J, 6, 610 10.1245/s10434-007-9354-3 10.1002/gcc.20366 10.1158/0008-5472.CAN-06-0031 10.1186/bcr2344 1995 Oxford University Press Oxford UK C.M. Bishop Neural Networks and Pattern Recognition 10.1111/j.1742-4658.2008.06846.x 10.1148/radiol.2532081718 10.1007/s10549-006-9288-7 10.1038/msb.2009.19 10.1016/j.ctrv.2009.12.002 10.5507/bp.2009.002 10.1023/A:1018727813904 10.1016/S0140-6736(96)10109-4 10.1093/annonc/mdj095 10.1073/pnas.0707772105 10.1073/pnas.0803513105 10.1200/JCO.2007.14.5375 10.1007/s10549-008-0128-9 10.1001/jama.295.21.2492 10.1158/1078-0432.CCR-06-1109 Carey L.A., 2008, TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer, J. Clin. Oncol, 26 10.1186/bcr1517 10.1371/journal.pone.0006693 10.1073/pnas.0409462102 10.1158/1078-0432.CCR-07-1658 10.1091/mbc.11.1.369 10.1091/mbc.e03-11-0794 10.1093/annonc/mdm504 10.1038/msb.2008.74 10.1089/cmb.2008.12TT 10.1371/journal.pone.0003478 10.1016/j.ccr.2006.10.009 10.1186/gb-2007-8-10-r215 10.1038/msb4100180 10.1200/JCO.2006.09.7550 10.1016/S1470-2045(07)70074-8 10.1158/1055-9965.EPI-04-0394 10.1093/annonc/mdn710 10.1007/BF00223866 10.1016/j.cancergencyto.2005.08.013 10.1186/1471-2105-8-291 10.1073/pnas.0437746100 10.1016/S0959-8049(09)70013-9 10.2174/156800907781662301 10.1158/1078-0432.CCR-06-3045 10.1158/1078-0432.CCR-08-0974 2001 Wiley New York USA R. Duda P. Hart D. Stork Pattern Classification 10.1023/A:1021874224490 Easton D.F., 1995, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium, Am. J. Hum. Genet, 56, 265 Eisinger F., 1996, Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer, Cancer Res, 56, 471 10.1038/msb4100125 10.1038/nature03445 10.1038/nchembio817 10.1056/NEJMoa0900212 10.1016/S0140-6736(94)91578-4 10.1136/jmg.2003.013805 10.1002/cncr.11688 10.1093/jnci/djg050 10.1186/1471-2407-6-96 10.1111/j.1365-2559.2006.02453.x 10.1073/pnas.0503793102 10.1007/s10334-008-0146-y 10.1007/s10549-008-0263-3 10.1038/ncb1973 10.1021/pr9008783 10.1073/pnas.0701361104 10.1093/annonc/mdp322 Gorski J.J., 2009, BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer, Breast Cancer Res. Treat Grushko T.A., 2002, Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers, Cancer Res, 62, 1481 10.1080/00313020701329914 10.1200/JCO.2006.06.5664 10.1126/science.2270482 10.5858/134.1.130 10.1155/2004/424395 10.1089/jir.2005.25.297 10.1023/A:1006141703224 10.1186/1471-2407-9-104 10.1038/sj.onc.1209875 10.1038/modpathol.3800969 10.2174/138161208786404362 10.1186/1471-2164-7-96 10.2217/fon.09.68 10.1038/nrc1609 10.1126/scisignal.2000356 10.1016/j.ejca.2008.09.034 10.1038/nature08467 10.1016/S0140-6736(95)91060-3 10.1002/path.1845 10.1016/j.breast.2004.06.003 10.1016/j.canlet.2009.02.034 10.1016/S0959-8049(97)89007-7 10.1111/j.1524-4741.2009.00789.x 10.3816/CBC.2009.n.005 10.1046/j.1432-1327.2000.01197.x 10.1200/JCO.2005.11.007 10.1186/bcr1771 10.1038/sj.onc.1205580 10.1186/bcr2261 10.1007/s10549-004-2172-4 10.1093/jnci/90.15.1138 10.1200/JCO.2002.09.023 10.1186/bcr1675 10.1371/journal.pbio.0000010 10.1083/jcb.200601018 10.1146/annurev.pharmtox.47.120505.105208 10.1200/JCO.2007.14.4147 10.1073/pnas.0711613105 10.1093/carcin/22.6.851 10.1038/modpathol.3800528 Lluch-Ariet M., 2008, On the implementation of HealthAgents: agent-based brain tumour diagnosis, Agent-technology and E-health, 5 10.1007/s10549-008-9926-3 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W 10.2174/138955709788922610 10.1158/0008-5472.CAN-06-0140 10.1093/carcin/bgn157 10.1016/j.breast.2007.11.031 10.1126/science.7545954 10.1002/ijc.10641 10.1002/ijc.22789 10.1002/cncr.22836 10.1038/nrc2713 10.1093/bioinformatics/btp558 10.1038/nrc1431 10.1016/j.molonc.2007.03.004 10.1101/gr.099622.109 10.1016/j.ccr.2006.10.008 10.1158/1078-0432.CCR-04-0220 O'Shaughnessy J., 2009, Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial, J. Clin. Oncol 10.1093/annonc/mdi213 10.1023/A:1006132427948 Palacios J., 2003, Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers, Clin. Cancer Res, 9, 3606 10.1200/JCO.2008.18.1370 10.1073/pnas.96.16.9212 10.1038/35021093 10.2174/157340507780619160 10.1172/JCI33295 10.1038/ng.2007.2 10.1002/path.1916 10.1002/cncr.22381 10.1200/JCO.2007.13.1748 10.1158/1078-0432.CCR-08-2132 10.1111/j.1365-2559.2007.02889.x 10.1186/bcr658 10.1158/1078-0432.CCR-05-2281 10.1136/jcp.2006.043869 10.1158/1078-0432.CCR-04-2421 Ryan P.D., 2009, Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy, J. Clin. Oncol, 27 10.1371/journal.pcbi.1000438 10.1073/pnas.0710134105 10.1158/1078-0432.CCR-08-1208 10.1038/nbt0402-370 10.1126/scisignal.2000352 10.1186/1471-2105-10-344 10.1186/bcr76 10.1093/bioinformatics/btp543 10.1517/14728222.12.9.1123 10.1038/ncponc0908 10.1093/annonc/mdn395 10.1016/j.pnmrs.2008.10.001 10.1158/0008-5472.CAN-07-5644 10.1073/pnas.0932692100 10.1186/bcr2242 10.1038/nature08645 10.1097/CCO.0b013e328312efba 10.1073/pnas.0237333100 10.1038/sj.bjc.6605031 10.1007/s10549-007-9756-8 10.1097/PPO.0b013e31818d839b 10.1200/JCO.2007.12.6557 10.1200/JCO.2005.01.7632 10.1007/s10552-009-9331-1 10.1038/ng1504 10.1148/radiol.2503081054 10.1158/1078-0432.CCR-06-2958 2002 Springer New York USA V.N. Vapnik The Nature of Statistical Learning Theory 10.1038/415530a 10.1016/S0092-8674(02)00615-3 10.1016/S0140-6736(97)07065-7 10.1007/s10549-008-0206-z 10.1056/NEJMoa021967 10.1083/jcb.200611114 10.1186/bcr1666 von Minckwitz G. Kaufmann M. Kűmmel S. 2008. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/- trastuzumab containing chemotherapy. In: San Antonio Breast Cancer Symposium San Antonio TX abstr 79. 10.1038/nrc2715 10.1148/radiol.2462070169 10.1002/path.2407 10.1007/s10549-008-0197-9 10.1016/j.cca.2008.10.014 10.1038/378789a0 10.1007/s10549-007-9810-6 10.1371/journal.pone.0000936 10.1016/j.jtbi.2009.05.018
Thông tin
Thông tin xuất bản

Wiley

Tập 4 Số 3

209-229

Thông tin tác giả